Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 8 (August)

1. The surgical learning curve for prostate cancer control after radical prostatectomy.
   J Natl Cancer Inst, 99(15): 1171-7. [Abstract] [Full-text]
2. Prospective study of fruit and vegetable intake and risk of prostate cancer.
   J Natl Cancer Inst, 99(15): 1200-9. [Abstract] [Full-text]
3. Cylindroma of the prostate.
   Am J Surg Pathol, 31(8): 1288-91. [Abstract] [Full-text]
4. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
   Am J Surg Pathol, 31(8): 1246-55. [Abstract] [Full-text]
5. Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma.
   Am J Surg Pathol, 31(8): 1225-30. [Abstract] [Full-text]
6. Genistein induces the metastasis suppressor kangai-1 which mediates its anti-invasive effects in TRAMP cancer cells.
   Biochem Biophys Res Commun, 361(1): 169-75. [Abstract] [Full-text]
7. Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells.
   Biochem Biophys Res Commun, 361(1): 189-95. [Abstract] [Full-text]
8. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
   Nature, 448(7153): 595-9. [Abstract] [Full-text]
9. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.
   Cancer Res, 67(15): 7525-33. [Abstract] [Full-text]
10. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.
    Cancer Res, 67(15): 7458-66. [Abstract] [Full-text]
11. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Cancer Res, 67(15): 7450-7. [Abstract] [Full-text]
12. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.
    Cancer Res, 67(15): 7439-49. [Abstract] [Full-text]
13. An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
    BJU Int, 100(3): 518-27. [Abstract] [Full-text]
14. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin.
    BJU Int, 100(3): 528-32. [Abstract] [Full-text]
15. Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
    BJU Int, 100(3): 533-5. [Abstract] [Full-text]
16. Does active surveillance for men with localized prostate cancer carry psychological morbidity?
    BJU Int, 100(3): 540-3. [Abstract] [Full-text]
17. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
    BJU Int, 100(3): 514-7. [Abstract] [Full-text]
18. Bad expression influences time to androgen escape in prostate cancer.
    BJU Int, 100(3): 691-6. [Abstract] [Full-text]
19. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.
    BJU Int, 100(3): 685-90. [Abstract] [Full-text]
20. A randomized controlled trial of topical glyceryl trinitrate before transrectal ultrasonography-guided biopsy of the prostate.
    BJU Int, 100(3): 536-8; discussion 538-9. [Abstract] [Full-text]
21. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance.
    BJU Int, 100(3): 544-51. [Abstract] [Full-text]
22. Radical prostatectomy for clinical T3 disease: expanding indications while optimizing cancer control and quality of life.
    Nat Clin Pract Urol, 4(8): 451-4. [Abstract] [Full-text]
23. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
    J Nucl Med, 48(8): 1327-37. [Abstract] [Full-text]
24. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.
    Mol Cell, 27(3): 380-92. [Abstract] [Full-text]
25. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
    Invest New Drugs, 25(5): 445-51. [Abstract] [Full-text]
26. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
    Cancer, 110(4): 906-10. [Abstract] [Full-text]
27. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
    BMC Cancer, 7: 142. [Abstract] [Full-text]
28. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy.
    J Gen Intern Med, 22(9): 1305-10. [Abstract] [Full-text]
29. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
    J Urol, 178(3): 1086-91. [Abstract] [Full-text]
30. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy.
    J Urol, 178(3): 990-5. [Abstract] [Full-text]
31. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.
    J Urol, 178(3): 826-31; discussion 831-2. [Abstract] [Full-text]
32. Predictors of histological disease progression in untreated, localized prostate cancer.
    J Urol, 178(3): 833-7. [Abstract] [Full-text]
33. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    J Urol, 178(3): 860-3; discussion 863. [Abstract] [Full-text]
34. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    J Urol, 178(3): 864-70; discussion 870-1. [Abstract] [Full-text]
35. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.
    J Urol, 178(3): 844-8; discussion 848. [Abstract] [Full-text]
36. Prospective evaluation of short-term impact and recovery of health related quality of life in men undergoing robotic assisted laparoscopic radical prostatectomy versus open radical prostatectomy.
    J Urol, 178(3): 854-8; discussion 859. [Abstract] [Full-text]
37. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
    J Urol, 178(3): 849-53; discussion 853; quiz 1129. [Abstract] [Full-text]
38. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
    J Urol, 178(3): 838-43; quiz 1129. [Abstract] [Full-text]
39. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.
    Endocrinology, 148(9): 4334-43. [Abstract] [Full-text]
40. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
    J Clin Oncol, 25(24): 3603-8. [Abstract] [Full-text]
41. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
    J Clin Oncol, 25(24): 3596-602. [Abstract] [Full-text]
42. Assessing individual risk for prostate cancer.
    J Clin Oncol, 25(24): 3582-8. [Abstract] [Full-text]
43. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer.
    J Clin Oncol, 25(24): 3576-81. [Abstract] [Full-text]
44. Monte Carlo calculation of rectal dose when using an intrarectal balloon during prostate radiation therapy.
    Med Dosim, 32(3): 151-6. [Abstract] [Full-text]
45. Steroid receptor RNA activator (SRA1): unusual bifaceted gene products with suspected relevance to breast cancer.
    Nucl Recept Signal, 5: e006. [Abstract] [Full-text]
46. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
    Oncology, 71(3): 168-75. [Abstract] [Full-text]
47. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Am J Surg Pathol, 31(9): 1351-5. [Abstract] [Full-text]
48. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
    Am J Surg Pathol, 31(9): 1323-9. [Abstract] [Full-text]
49. The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells.
    Cancer Lett, 255(2): 300-6. [Abstract] [Full-text]
50. TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer.
    Cancer Immunol Immunother, 56(11): 1785-93. [Abstract] [Full-text]
51. Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells.
    Biochem Biophys Res Commun, 362(1): 212-7. [Abstract] [Full-text]
52. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
    Nat Clin Pract Oncol, 4(9): 551-4. [Abstract] [Full-text]
53. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    J Clin Oncol, 25(25): 3965-70. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.